Should we prescribe systemic antibiotics alongside periodontal therapy for diabetic patients?

IF 2.3 Q3 Dentistry
Sophie Rimmer, Marianne Dobson
{"title":"Should we prescribe systemic antibiotics alongside periodontal therapy for diabetic patients?","authors":"Sophie Rimmer, Marianne Dobson","doi":"10.1038/s41432-024-01096-2","DOIUrl":null,"url":null,"abstract":"This single-centre, short-term randomized control trial (RCT) assesses the effect of systemic amoxicillin and metronidazole as an adjunct to SRP in patients with severe periodontitis and type 2 diabetes mellitus (T2DM) on glycaemic control, over a 3-month period. The authors hypothesize that adjunctive systemic antibiotics will decrease systemic inflammation and subsequently improve glucose control. Baseline periodontal examinations and haematological tests were performed for all subjects. Subsequently, subgingival scaling and root planning (SRP) procedures were performed by a single periodontist for both the test and control groups. The test group received 500 mg amoxicillin and 200 mg metronidazole TDS for 7 days in the same week of the SRP procedure. Three months later, periodontal examinations were repeated by blinded examiners and haematological tests were repeated. Maintenance periodontal therapy was provided at this time. A convenience sample of patients visiting the periodontal department between 2016-2022 was used. Participants included were aged 40–75; diagnosed with T2DM for >2 years; HbA1c of 6.5–10%, had stable medication regimens and >15 remaining teeth. Participants had a periodontal diagnosis of generalized severe chronic periodontitis or stage III-IV generalized periodontitis based on the 1999 and 2018 classifications respectively. Exclusion criteria related to coexisting inflammatory or infectious diseases (e.g. malignancy, coronary heart disease or hepatitis); adjustment in diet or glycaemic control strategy; severe diabetic complications; pregnancy or lactation; allergies to amoxicillin or metronidazole; periodontal treatment or antibiotics within 3 months prior; smoking and alcohol abuse. The primary clinical outcome was a change in HbA1c. Secondary outcomes included the effect on periodontal parameters and haematological markers of inflammation. Periodontal parameters measured were probing depth (PD), bleeding index (BI), Plaque index (PI), periodontally inflamed surface area (PISA), and clinical attachment level (CAL). Haematological parameters were glycated haemoglobin (HbA1c), fasting blood glucose (FBG), neutrophil-to-lymphocyte ratio (NLR), and white blood cell (WBC) count. For data analysis, poorly controlled T2DM was defined as baseline HbA1c > 7.5%. Statistical significance was defined as p < 0.05. Analysis within and between the two groups was analysed with Student’s t-tests when data followed a normal distribution and the Mann-Whitney U test for non-normally distributed data. Chi-square testing was used to compare categorical variables. Uni- and multivariable binary logistic regression was employed to analyze the effectors related to HbA1c decrease. Intention-to-treat analysis was carried out for all enroled participants. 49 participants were enroled in the study; 23 were assigned to the SRP-only group and 26 to the SRP + antibiotics group. Nine participants were lost to follow-up. HbA1c levels decreased significantly after treatment in both the SRP group (7.6 ± 0.98% vs. 7.22 ± 0.88%, p = 0.001) and the SRP + antibiotics group (7.95 ± 1.23% vs 7.42 ± 1.14%, p = 0.004). Following multivariable regression analysis, female sex, adjunctive antibiotic use and high baseline HbA1c levels were associated with a greater decrease in HbA1c levels following periodontal therapy (OR = 9.358, 95%CI: 1.863–47.015; OR = 4.551, 95%CI: 1.012–20.463; OR = 7.162, 95% CI:1.359–37.753). Periodontal parameters significantly improved by a similar amount in both groups after treatment (p < 0.05). When the baseline PD was >6 mm, the SRP+ antibiotic group had more sites of improvement in PD than the SRP only group (698 sites vs 545 sites, p = 0.008). SRP alone and SRP with adjunctive antibiotics both proved beneficial for improving glycaemic control and periodontal health at 3 months following periodontal therapy. Participants with baseline HbA1c > 7.5% were more likely to show an improvement in HbA1c when receiving adjunctive antibiotics. Adjunctive antibiotic use slightly increased the degree of improvement in probing depths for patients with pocket depths >6 mm and T2DM.","PeriodicalId":12234,"journal":{"name":"Evidence-based dentistry","volume":"26 1","pages":"48-49"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based dentistry","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s41432-024-01096-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Dentistry","Score":null,"Total":0}
引用次数: 0

Abstract

This single-centre, short-term randomized control trial (RCT) assesses the effect of systemic amoxicillin and metronidazole as an adjunct to SRP in patients with severe periodontitis and type 2 diabetes mellitus (T2DM) on glycaemic control, over a 3-month period. The authors hypothesize that adjunctive systemic antibiotics will decrease systemic inflammation and subsequently improve glucose control. Baseline periodontal examinations and haematological tests were performed for all subjects. Subsequently, subgingival scaling and root planning (SRP) procedures were performed by a single periodontist for both the test and control groups. The test group received 500 mg amoxicillin and 200 mg metronidazole TDS for 7 days in the same week of the SRP procedure. Three months later, periodontal examinations were repeated by blinded examiners and haematological tests were repeated. Maintenance periodontal therapy was provided at this time. A convenience sample of patients visiting the periodontal department between 2016-2022 was used. Participants included were aged 40–75; diagnosed with T2DM for >2 years; HbA1c of 6.5–10%, had stable medication regimens and >15 remaining teeth. Participants had a periodontal diagnosis of generalized severe chronic periodontitis or stage III-IV generalized periodontitis based on the 1999 and 2018 classifications respectively. Exclusion criteria related to coexisting inflammatory or infectious diseases (e.g. malignancy, coronary heart disease or hepatitis); adjustment in diet or glycaemic control strategy; severe diabetic complications; pregnancy or lactation; allergies to amoxicillin or metronidazole; periodontal treatment or antibiotics within 3 months prior; smoking and alcohol abuse. The primary clinical outcome was a change in HbA1c. Secondary outcomes included the effect on periodontal parameters and haematological markers of inflammation. Periodontal parameters measured were probing depth (PD), bleeding index (BI), Plaque index (PI), periodontally inflamed surface area (PISA), and clinical attachment level (CAL). Haematological parameters were glycated haemoglobin (HbA1c), fasting blood glucose (FBG), neutrophil-to-lymphocyte ratio (NLR), and white blood cell (WBC) count. For data analysis, poorly controlled T2DM was defined as baseline HbA1c > 7.5%. Statistical significance was defined as p < 0.05. Analysis within and between the two groups was analysed with Student’s t-tests when data followed a normal distribution and the Mann-Whitney U test for non-normally distributed data. Chi-square testing was used to compare categorical variables. Uni- and multivariable binary logistic regression was employed to analyze the effectors related to HbA1c decrease. Intention-to-treat analysis was carried out for all enroled participants. 49 participants were enroled in the study; 23 were assigned to the SRP-only group and 26 to the SRP + antibiotics group. Nine participants were lost to follow-up. HbA1c levels decreased significantly after treatment in both the SRP group (7.6 ± 0.98% vs. 7.22 ± 0.88%, p = 0.001) and the SRP + antibiotics group (7.95 ± 1.23% vs 7.42 ± 1.14%, p = 0.004). Following multivariable regression analysis, female sex, adjunctive antibiotic use and high baseline HbA1c levels were associated with a greater decrease in HbA1c levels following periodontal therapy (OR = 9.358, 95%CI: 1.863–47.015; OR = 4.551, 95%CI: 1.012–20.463; OR = 7.162, 95% CI:1.359–37.753). Periodontal parameters significantly improved by a similar amount in both groups after treatment (p < 0.05). When the baseline PD was >6 mm, the SRP+ antibiotic group had more sites of improvement in PD than the SRP only group (698 sites vs 545 sites, p = 0.008). SRP alone and SRP with adjunctive antibiotics both proved beneficial for improving glycaemic control and periodontal health at 3 months following periodontal therapy. Participants with baseline HbA1c > 7.5% were more likely to show an improvement in HbA1c when receiving adjunctive antibiotics. Adjunctive antibiotic use slightly increased the degree of improvement in probing depths for patients with pocket depths >6 mm and T2DM.
对于糖尿病患者,我们应该在牙周治疗的同时开全身性抗生素吗?
设计:这项单中心、短期随机对照试验(RCT)评估了阿莫西林和甲硝唑作为SRP辅助治疗严重牙周炎和2型糖尿病(T2DM)患者3个月的血糖控制效果。作者假设,辅助全身性抗生素将减少全身性炎症,随后改善血糖控制。对所有受试者进行基线牙周检查和血液学检查。随后,实验组和对照组分别由一名牙周病医生进行龈下刮治和牙根规划(SRP)手术。试验组在SRP程序的同一周内给予阿莫西林500 mg和甲硝唑200 mg TDS,连续7天。3个月后,再次进行盲法牙周检查和血液学检查。此时提供牙周维持性治疗。病例选择:选取2016-2022年间就诊牙周科的患者作为方便样本。参与者年龄在40-75岁之间;诊断为2型糖尿病2年;HbA1c 6.5-10%,用药方案稳定,余牙bbb15颗。根据1999年和2018年的分类,参与者的牙周诊断分别为广泛性重度慢性牙周炎或III-IV期广泛性牙周炎。与共存的炎症或传染病(如恶性肿瘤、冠心病或肝炎)有关的排除标准;调整饮食或血糖控制策略;严重的糖尿病并发症;孕期或哺乳期;对阿莫西林或甲硝唑过敏;3个月内接受牙周治疗或抗生素治疗;吸烟和酗酒。主要临床结果是HbA1c的改变。次要结局包括对牙周参数和炎症血液学指标的影响。数据分析:测量牙周参数:探探深度(PD)、出血指数(BI)、菌斑指数(PI)、牙周炎症表面积(PISA)、临床附着水平(CAL)。血液学参数包括糖化血红蛋白(HbA1c)、空腹血糖(FBG)、中性粒细胞与淋巴细胞比率(NLR)和白细胞(WBC)计数。在数据分析中,控制不良的T2DM定义为基线HbA1c为7.5%。统计显著性定义为p结果:49名受试者入组研究;仅SRP组23例,SRP +抗生素组26例。9名参与者未能随访。SRP组(7.76±0.98% vs 7.22±0.88%,p = 0.001)和SRP +抗生素组(7.95±1.23% vs 7.42±1.14%,p = 0.004)治疗后HbA1c水平均显著降低。多变量回归分析显示,女性、使用辅助抗生素和高基线HbA1c水平与牙周治疗后HbA1c水平的显著下降相关(OR = 9.3558, 95%CI: 1.863-47.015;Or = 4.551, 95%ci: 1.012-20.463;Or = 7.162, 95% ci:1.359-37.753)。治疗后两组患者牙周参数均有相似程度的改善(p = 6 mm), SRP+抗生素组PD改善部位多于单纯SRP组(698个部位vs 545个部位,p = 0.008)。结论:在牙周治疗后3个月,单用SRP和辅助抗生素均可改善血糖控制和牙周健康。基线HbA1c为7.5%的参与者在接受辅助抗生素治疗后更有可能出现HbA1c的改善。对于口袋深度为bb60 ~ 6mm和T2DM的患者,辅助抗生素的使用略微提高了探查深度的改善程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Evidence-based dentistry
Evidence-based dentistry Dentistry-Dentistry (all)
CiteScore
2.50
自引率
0.00%
发文量
77
期刊介绍: Evidence-Based Dentistry delivers the best available evidence on the latest developments in oral health. We evaluate the evidence and provide guidance concerning the value of the author''s conclusions. We keep dentistry up to date with new approaches, exploring a wide range of the latest developments through an accessible expert commentary. Original papers and relevant publications are condensed into digestible summaries, drawing attention to the current methods and findings. We are a central resource for the most cutting edge and relevant issues concerning the evidence-based approach in dentistry today. Evidence-Based Dentistry is published by Springer Nature on behalf of the British Dental Association.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书